Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 186

1.

Striatal histone modifications in models of levodopa-induced dyskinesia.

Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG.

J Neurochem. 2008 Jul;106(1):486-94. doi: 10.1111/j.1471-4159.2008.05417.x. Epub 2008 Jul 1.

2.

Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.

Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.

Biol Psychiatry. 2009 Sep 15;66(6):603-13. doi: 10.1016/j.biopsych.2009.04.025. Epub 2009 Jun 11.

PMID:
19520364
3.

ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.

Pavón N, Martín AB, Mendialdua A, Moratalla R.

Biol Psychiatry. 2006 Jan 1;59(1):64-74. Epub 2005 Sep 1.

PMID:
16139809
4.

Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.

Lebel M, Chagniel L, Bureau G, Cyr M.

Neurobiol Dis. 2010 Apr;38(1):59-67. doi: 10.1016/j.nbd.2009.12.027. Epub 2010 Jan 11.

PMID:
20060905
5.

Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.

Errico F, Bonito-Oliva A, Bagetta V, Vitucci D, Romano R, Zianni E, Napolitano F, Marinucci S, Di Luca M, Calabresi P, Fisone G, Carta M, Picconi B, Gardoni F, Usiello A.

Exp Neurol. 2011 Dec;232(2):240-50. doi: 10.1016/j.expneurol.2011.09.013. Epub 2011 Sep 17.

PMID:
21946266
6.

Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.

Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM.

Exp Neurol. 2003 Oct;183(2):458-68.

PMID:
14552886
7.

Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia.

Santini E, Valjent E, Usiello A, Carta M, Borgkvist A, Girault JA, Hervé D, Greengard P, Fisone G.

J Neurosci. 2007 Jun 27;27(26):6995-7005.

8.
9.

Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.

Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.

Neurobiol Dis. 2009 Aug;35(2):184-92. doi: 10.1016/j.nbd.2008.11.010. Epub 2008 Dec 9.

PMID:
19118628
10.

Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.

Silverdale MA, Crossman AR, Brotchie JM.

Exp Neurol. 2002 Mar;174(1):21-8.

PMID:
11869030
11.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
12.

Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.

Lane EL, Vercammen L, Cenci MA, Brundin P.

Exp Neurol. 2009 Sep;219(1):355-8. doi: 10.1016/j.expneurol.2009.04.010. Epub 2009 Apr 22.

PMID:
19393238
13.

Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia.

Zeng BY, Iravani MM, Jackson MJ, Rose S, Parent A, Jenner P.

Neurobiol Dis. 2010 Dec;40(3):599-607. doi: 10.1016/j.nbd.2010.08.004. Epub 2010 Aug 14.

PMID:
20713157
14.

Additive effects of histone deacetylase inhibitors and amphetamine on histone H4 acetylation, cAMP responsive element binding protein phosphorylation and DeltaFosB expression in the striatum and locomotor sensitization in mice.

Shen HY, Kalda A, Yu L, Ferrara J, Zhu J, Chen JF.

Neuroscience. 2008 Dec 2;157(3):644-55. doi: 10.1016/j.neuroscience.2008.09.019. Epub 2008 Sep 16.

PMID:
18848971
15.

Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms.

Giorgi M, D'Angelo V, Esposito Z, Nuccetelli V, Sorge R, Martorana A, Stefani A, Bernardi G, Sancesario G.

Eur J Neurosci. 2008 Sep;28(5):941-50. doi: 10.1111/j.1460-9568.2008.06387.x. Epub 2008 Aug 20.

PMID:
18717735
16.

Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.

Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.

Mov Disord. 2006 Jan;21(1):9-17.

PMID:
16127720
17.

Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

Alcacer C, Santini E, Valjent E, Gaven F, Girault JA, Hervé D.

J Neurosci. 2012 Apr 25;32(17):5900-10. doi: 10.1523/JNEUROSCI.0837-12.2012.

18.

L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain.

Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV.

Neurobiol Dis. 2005 Mar;18(2):323-35.

PMID:
15686961
19.
20.

Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.

Guigoni C, Dovero S, Aubert I, Li Q, Bioulac BH, Bloch B, Gurevich EV, Gross CE, Bezard E.

Eur J Neurosci. 2005 Jul;22(1):283-7.

PMID:
16029219

Supplemental Content

Support Center